198 related articles for article (PubMed ID: 11145256)
1. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI.
Glickman JN; Wang H; Das KM; Goyal RK; Spechler SJ; Antonioli D; Odze RD
Am J Surg Pathol; 2001 Jan; 25(1):87-94. PubMed ID: 11145256
[TBL] [Abstract][Full Text] [Related]
2. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
3. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
Liu GS; Gong J; Cheng P; Zhang J; Chang Y; Qiang L
World J Gastroenterol; 2005 Oct; 11(40):6360-5. PubMed ID: 16419166
[TBL] [Abstract][Full Text] [Related]
4. [Cytokeratin 7 and 20 in Barrett's esophagus].
Arra A; Nieva NB; Rey N; Fernández AO
Rev Fac Cien Med Univ Nac Cordoba; 2005; 62(3):57-62. PubMed ID: 16972735
[TBL] [Abstract][Full Text] [Related]
5. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
8. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia.
Csendes A; Smok G; Quiroz J; Burdiles P; Rojas J; Castro C; Henríquez A
Am J Gastroenterol; 2002 Mar; 97(3):554-60. PubMed ID: 11922546
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus.
Gulmann C; Shaqaqi OA; Grace A; Leader M; Patchett S; Butler D; Kay E
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):142-7. PubMed ID: 15354740
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
Ormsby AH; Goldblum JR; Rice TW; Richter JE; Falk GW; Vaezi MF; Gramlich TL
Hum Pathol; 1999 Mar; 30(3):288-94. PubMed ID: 10088547
[TBL] [Abstract][Full Text] [Related]
12. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus.
Loughney T; Maydonovitch CL; Wong RK
Am J Gastroenterol; 1998 Jun; 93(6):916-9. PubMed ID: 9647018
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
Shearer C; Going J; Neilson L; Mackay C; Stuart RC
Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
[TBL] [Abstract][Full Text] [Related]
14. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
15. Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction.
Pera M
World J Surg; 2003 Sep; 27(9):999-1008; discussion 1006-8. PubMed ID: 12917764
[TBL] [Abstract][Full Text] [Related]
16. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data.
Hirota WK; Loughney TM; Lazas DJ; Maydonovitch CL; Rholl V; Wong RK
Gastroenterology; 1999 Feb; 116(2):277-85. PubMed ID: 9922307
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
[TBL] [Abstract][Full Text] [Related]
18. [Histochemical diagnosis of short segment Barrett's esophagus].
Fujiyama Y; Ishizuka I; Koyama S
Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
[TBL] [Abstract][Full Text] [Related]
19. Etiology of intestinal metaplasia at the gastroesophageal junction.
Balaji NS; DeMeester SR; Wickramasinghe KS; Hagen JA; Peters JH; DeMeester TR
Surg Endosc; 2003 Jan; 17(1):43-8. PubMed ID: 12364989
[TBL] [Abstract][Full Text] [Related]
20. Bile and acid reflux in long and short segment Barrett's esophagus, and in reflux disease.
Pfaffenbach B; Hullerum J; Orth KH; Langer M; Stabenow-Lohbauer U; Lux G
Z Gastroenterol; 2000 Jul; 38(7):565-70. PubMed ID: 10965553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
